Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma.
Comput Struct Biotechnol J
; 20: 4390-4401, 2022.
Article
in En
| MEDLINE
| ID: mdl-36051873
ACAP1; ACAP1, ADP-ribosylation factor (Arf)-GTPase-activating protein (GAP) with coiled-coil, ankyrin repeat and PH domains 1; Arf6, ADP-ribosylation factor 6; CAMs, cell adhesion molecules; CI, confidence interval; DEGs, differentially expressed genes; DSS, disease specific survival; GEFs, guanine nucleotide exchange factors; GEPIA, gene expression profiling interactive analysis; GO, gene ontology; GSEA, Gene Set Enrichment Analysis; GTEx, genotype-tissue expression; HR, hazard ratio; ICB, immune checkpoint blockade; Immune infiltrates; Immunotherapy; KEGG, Kyoto encyclopedia of genes and genomes; LUAD, lung adenocarcinoma; Lung adenocarcinoma; OS, overall survival; PD-1, programmed death receptor 1; PD-L1, programmed death receptor ligand 1; PPI, proteinprotein interaction; Prognosis; TCGA, the cancer genome atlas; TIME, tumor immune microenvironment; TIMER, tumor immune estimation resource; TME, tumor microenvironment; qRT-PCR, quantitative reverse-transcription polymerase chain reaction
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Comput Struct Biotechnol J
Year:
2022
Document type:
Article